Saturday , September 22 2018
Home / Resources / Videos / ADA 2017 / Thomas Seck Current Interview

Thomas Seck Current Interview

Mar 17, 2018
 

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have another exclusive interview from the ADA 2017 Scientific Sessions in San Diego, CA.

Thomas Seck is Vice President of US Clinical Development and Medical Affairs Primary Care at Boehringer Ingelheim.

Thomas earned his medical degree from the University of Mainz in Germany. He completed his residency and fellowship within the Department of Endocrinology and Metabolism, at the University of Heidelberg, Germany. Thomas completed a postdoctoral fellowship within the Department of Cell Biology at Yale University, New Haven. Following his postdoctoral fellowship, Thomas accepted a position as Associate Professor Endocrinology and Metabolism at the University of Bochum, Germany. Before he joined Boehringer Ingelheim in 2011, he worked in the USA for over 5 years in the area of Drug Development and Medical Affairs within the cardiometabolic field at Merck.

Featured videos include:

Pt.1: Introduction And Empagliflozin For Diabetes

Pt.2: New Data on Empagliflozin

Pt.3: Empagliflozin Precautions and Side Effects

Pt.4: Empagliflozin Effects on Cardiovascular Disease

Pt.5: The Cost of Empagliflozin for Patients

Pt.6: Cardiovascular Disease And Type 2 Diabetes

Pt.7: The Future For Boehringer Ingelheim

Pt.8: Empagliflozin Effects On Prediabetes

Pt.9: Final Thoughts

or view the complete interview here: Complete Interview.

To read the transcript of the full interview, click here.